Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (281-290 of 454) with videos related to

Pageof 46
Sort By:
Kidney International|February 6, 2018
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCharles R Swanepoel, Mohamed G Atta, Vivette D D'Agati, et al.
Journal of General Internal Medicine|December 15, 2023
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by SexMargaret K Yu, Priya Vart, Niels Jongs, et al.
Neurology|June 18, 2024
Associations of Cerebral Small Vessel Disease and Chronic Kidney Disease in Patients With Acute Intracerebral Hemorrhage: A Cross-Sectional StudyPhilip S Nash, Simon Fandler-Höfler, Gareth Ambler, et al.
Journal of the American Society of Nephrology : JASN|August 17, 2022
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKDNiels Jongs, Glenn M Chertow, Tom Greene, et al.
European Journal of Heart Failure|May 15, 2026
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trialBrendon L Neuen, Henri Lu, Muthiah Vaduganathan, et al.
Kidney International Reports|March 8, 2022
The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor AntagonistsMichele Provenzano, Niels Jongs, Priya Vart, et al.
The Annals of Occupational Hygiene|November 28, 2012
Comparison of algorithm-based estimates of occupational diesel exhaust exposure to those of multiple independent raters in a population-based case-control studyMelissa C Friesen, Anjoeka Pronk, David C Wheeler, et al.
JMIR Formative Research|April 16, 2026
A Digital Inclusion Intervention to Improve Access to a Digital Health Intervention Among Digitally Excluded Adults: Mixed Methods Pilot Randomized Controlled TrialChristy Walklin, Juliet Briggs, Siobhan Freeman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2017
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal ProtectionMarion M Mafham, Natalie Staplin, Jonathan Emberson, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2012
Effects of phosphate binders in moderate CKDGeoffrey A Block, David C Wheeler, Martha S Persky, et al.
Pageof 46

Showing results (281-290 of 454) with videos related to

Sort By:
Pageof 46
Kidney International|February 6, 2018
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCharles R Swanepoel, Mohamed G Atta, Vivette D D'Agati, et al.
Journal of General Internal Medicine|December 15, 2023
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by SexMargaret K Yu, Priya Vart, Niels Jongs, et al.
Neurology|June 18, 2024
Associations of Cerebral Small Vessel Disease and Chronic Kidney Disease in Patients With Acute Intracerebral Hemorrhage: A Cross-Sectional StudyPhilip S Nash, Simon Fandler-Höfler, Gareth Ambler, et al.
Journal of the American Society of Nephrology : JASN|August 17, 2022
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKDNiels Jongs, Glenn M Chertow, Tom Greene, et al.
European Journal of Heart Failure|May 15, 2026
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trialBrendon L Neuen, Henri Lu, Muthiah Vaduganathan, et al.
Kidney International Reports|March 8, 2022
The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor AntagonistsMichele Provenzano, Niels Jongs, Priya Vart, et al.
The Annals of Occupational Hygiene|November 28, 2012
Comparison of algorithm-based estimates of occupational diesel exhaust exposure to those of multiple independent raters in a population-based case-control studyMelissa C Friesen, Anjoeka Pronk, David C Wheeler, et al.
JMIR Formative Research|April 16, 2026
A Digital Inclusion Intervention to Improve Access to a Digital Health Intervention Among Digitally Excluded Adults: Mixed Methods Pilot Randomized Controlled TrialChristy Walklin, Juliet Briggs, Siobhan Freeman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2017
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal ProtectionMarion M Mafham, Natalie Staplin, Jonathan Emberson, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2012
Effects of phosphate binders in moderate CKDGeoffrey A Block, David C Wheeler, Martha S Persky, et al.
Pageof 46